Nurses can help manage drug interactions in HIV/Hep C treatment

Nurses can help manage drug interactions in HIV/Hep C treatment

(HealthDay)—Drug interactions between antiretroviral therapy (ART) and direct-acting antivirals (DAAs) pose a clinical challenge in patients with HIV/hepatitis C virus (HCV) coinfection, according to an article published online Dec. 17 in the Journal of the Association of Nurses in AIDS Care.

Laura E. Starbird, Ph.D., R.N., from the Columbia University School of Nursing in New York City, and colleagues provide guidance for registered nurses and who care for patients coinfected with HIV and HCV.

The authors note that diligence is required in coprescribing to avoid potentially toxic . Administration of simeprevir is the most problematic with ART, with 76 to 88 percent of persons living with HIV potentially encountering a contraindicated drug-drug interaction. The fewest interactions with ART are seen for sofosbuvir, with prevalence ranging from 0 to 24 percent. In the presence of sofosbuvir, the only contraindicated ART is tipranavir. Nurses should be prepared to initiate ART switches at least one month before initiation of DAA. When an ART modification is made to accommodate DAAs, the DAA should not be started for at least two weeks after regimen change. To ensure , HIV viral load should be checked within two to eight weeks after switching. If switching back, it is recommended to wait two weeks after completing DAA until resuming original ART regimen.

"Nurses are in a position to identify, mitigate, and manage ART/DAA drug interactions and should be knowledgeable in this area," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

More information: Abstract/Full Text (subscription or payment may be required)

Copyright © 2019 HealthDay. All rights reserved.

Citation: Nurses can help manage drug interactions in HIV/Hep C treatment (2020, January 2) retrieved 28 February 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

HBV reactivation is concern with DAA Tx in HBV-HCV coinfection


Feedback to editors